39 research outputs found
Drosophila dyskerin is required for somatic stem cell homeostasis
Drosophila represents an excellent model to dissect the roles played by the evolutionary conserved
family of eukaryotic dyskerins. These multifunctional proteins are involved in the formation of H/
ACA snoRNP and telomerase complexes, both involved in essential cellular tasks. Since fly telomere
integrity is guaranteed by a different mechanism, we used this organism to investigate the specific
role played by dyskerin in somatic stem cell maintenance. To this aim, we focussed on Drosophila
midgut, a hierarchically organized and well characterized model for stemness analysis. Surprisingly,
the ubiquitous loss of the protein uniquely affects the formation of the larval stem cell niches, without
altering other midgut cell types. The number of adult midgut precursor stem cells is dramatically
reduced, and this effect is not caused by premature differentiation and is cell-autonomous. Moreover,
a few dispersed precursors found in the depleted midguts can maintain stem identity and the ability to
divide asymmetrically, nor show cell-growth defects or undergo apoptosis. Instead, their loss is mainly
specifically dependent on defective amplification. These studies establish a strict link between dyskerin
and somatic stem cell maintenance in a telomerase-lacking organism, indicating that loss of stemness
can be regarded as a conserved, telomerase-independent effect of dyskerin dysfunction
Modulation of the activity of histone acetyltransferases by long chain alkylidenemalonates (LoCAMs)
n/
Potential Anti-SARS-CoV-2 Molecular Strategies
Finding effective antiviral molecular strategies was a main concern in the scientific community when the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged at the end of 2019 as an easily transmissible and potentially deadly β-coronavirus able to cause the coronavirus disease 19 (COVID-19), which famously led to one of the most worrying pandemics in recent times. Other members of this zoonotic pathogenic family were already known before 2019, but apart from the SARS-CoV, which was responsible of severe acute respiratory syndrome (SARS) pandemic in 2002/2003, and Middle East respiratory syndrome coronavirus (MERS-CoV), whose main impact on humans is geographically restricted to Middle Eastern countries, the other human β-coronaviruses known at that time were those typically associated with common cold symptoms which had not led to the development of any specific prophylactic or therapeutic measures. Although SARS-CoV-2 and its mutations are still causing illness in our communities, COVID-19 is less deadly than before and we are returning to normality. Overall, the main lesson learnt after the past few years of pandemic is that keeping our bodies healthy and immunity defenses strong using sport, nature-inspired measures, and using functional foods are powerful weapons for preventing the more severe forms of illness caused by SARS-CoV-2 and, from a more molecular perspective, that finding drugs with mechanisms of action involving biological targets conserved within the different mutations of SARS-CoV-2—and possibly within the entire family of β-coronaviruses—gives more therapeutic opportunities in the scenario of future pandemics based on these pathogens. In this regard, the main protease (Mpro), having no human homologues, offers a lower risk of off-target reactivity and represents a suitable therapeutic target in the search for efficacious, broad-spectrum anti-β-coronavirus drugs. Herein, we discuss on the above points and also report some molecular approaches presented in the past few years to counteract the effects of β-coronaviruses, with a special focus on SARS-CoV-2 but also MERS-CoV
Protein-Targeting Drug Discovery
Protein-driven biological processes play a fundamental role in biomedicine because they are related to pathologies of enormous social impact, such as cancer, neuropathies, and viral diseases, including the one at the origin of the recent COVID-19 pandemic [...
In Silico Investigation on the Interaction of Chiral Phytochemicals from Opuntia ficus-indica with SARS-CoV-2 Mpro
Opuntia ficus-indica is a cactaceous plant native to America but, nowadays, widely found
worldwide, having been the most common domesticated species of cactus grown as a crop plant
in semiarid and arid parts of the globe, including several Mediterranean basin countries. Opuntia
ficus-indica can be regarded as a medicinal plant, being source of numerous bioactive phytochemicals
such as vitamins, polyphenols, and amino acids. The urgent need for therapeutic treatments for the
COronaVIrus Disease 19 (COVID-19), caused by the Severe Acute Respiratory Syndrome (SARS)-
Coronavirus (CoV)-2, justifies the great attention currently being paid not only to repurposed antiviral
drugs, but also to natural products and herbal medications. In this context, the anti-COVID-19 utility
of Opuntia ficus-indica as source of potential antiviral drugs was investigated in this work on the
basis of the activity of some of its phytochemical constituents. The antiviral potential was evaluated
in silico in docking experiments with Mpro, i.e., the main protease of SARS-CoV-2, that is one of
the most investigated protein targets of therapeutic strategies for COVID-19. By using two webbased molecular docking programs (1-Click Mcule and COVID-19 Docking Server), we found, for several flavonols and flavonol glucosides isolated from Opuntia ficus-indica, good binding affinities
for Mpro, and in particular, binding energies lower than â7.0 kcal/mol were predicted for astragalin,
isorhamnetin, isorhamnetin 3-O-glucoside, 3-O-caffeoyl quinic acid, and quercetin 5,40-dimethyl ether. Among these compounds, the chiral compound astragalin showed in our in silico studies the highest affinity for Mpro (â8.7 kcal/mol) and also a low toxicity profile, emerging, thus, as an interesting protease inhibitor candidate for anti-COVID-19 strategies
Willardiine and Its Synthetic Analogues: Biological Aspects and Implications in Peptide Chemistry of This Nucleobase Amino Acid
Willardiine is a nonprotein amino acid containing uracil, and thus classified as nucleobase amino acid or nucleoamino acid, that together with isowillardiine forms the family of uracilylalanines isolated more than six decades ago in higher plants. Willardiine acts as a partial agonist of ionotropic glutamate receptors and more in particular it agonizes the non-N-methyl-D-aspartate (non-NMDA) receptors of L-glutamate: ie. the α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) and kainate receptors. Several analogues and derivatives of willardiine have been synthesised in the laboratory in the last decades and these compounds show different binding affinities for the non-NMDA receptors. More in detail, the willardiine analogues have been employed not only in the investigation of the structure of AMPA and kainate receptors, but also to evaluate the effects of receptor activation in the various brain regions. Remarkably, there are a number of neurological diseases determined by alterations in glutamate signaling, and thus, ligands for AMPA and kainate receptors deserve attention as potential neurodrugs. In fact, similar to willardiine its analogues often act as agonists of AMPA and kainate receptors. A particular importance should be recognized to willardiine and its thymine-based analogue AlaT also in the peptide chemistry field. In fact, besides the naturally-occurring short nucleopeptides isolated from plant sources, there are different examples in which this class of nucleoamino acids was investigated for nucleopeptide development. The applications are various ranging from the realization of nucleopeptide/DNA chimeras for diagnostic applications, and nucleoamino acid derivatization of proteins for facilitating protein-nucleic acid interaction, to nucleopeptide-nucleopeptide molecular recognition for nanotechnological applications. All the above aspects on both chemistry and biotechnological applications of willardine/willardine-analogues and nucleopeptide will be reviewed in this work
The Healing Power of Clean Rivers: In Silico Evaluation of the Antipsoriatic Potential of Apiin and Hyperoside Plant Metabolites Contained in River Waters
Humanity may benefit greatly from intact riverine ecosystems not only because they supply water to be used in the most common human activities, but also for the effects that clean rivers can have on human health. Herein, we used a computational approach to show that some phytochemicals produced by riparian plants as secondary metabolites, which are naturally released into river waters, can have therapeutic properties. These include antipsoriatic activities which we demonstrated in silico by modelling the interaction of apiin, guanosine and hyperoside, a few main river plant metabolites, with NF-kB, IL-17 and IL-36, which are recognized targets involved in psoriasis disease. In particular, we found that apiin and hyperoside are endowed with docking energies and binding affinities which are more favorable than the known reference inhibitors of the three protein targets whilst, in silico, guanosine shows comparable activity with respect to the inhibitors of IL-36 and NF-kB. The low skin permeation (logKp < −8) we predicted for apiin and hyperoside led us to hypothesize their possible utilization as topic antipsoriatic therapeutics, and in particular after PAINS (pan-assay interference compounds) score evaluation, we reached the conclusion that apiin, with no predicted tendency to react nonspecifically with the numerous targets involved in the biological cellular pathways, is particularly interesting for the desired therapeutic application